Arthritis and Lupus Drugs Pulled Off by Pharma Companies

.

Arthritis and Lupus Drugs Pulled Off by Pharma Companies

Following many deaths, rheumatoid arthritis and lupus drugs are being pulled off by Swiss pharmaceutical companies Roche and Biogen. After being observed by monitoring board, the two drugs were found to be immensely infectious and even deadly in some cases.

Ocrelizumab is still reportedly being tested for people who suffer from relapsing remitting multiple sclerosis. The expected sale of 800 million francs is therefore being denied by Roche. Zurich exchange reported a dip of 0.6% at 179.60 Swiss francs in sales of Roche.

Roche had said that before the drug was proved to be causing some serious infections, earlier last year, at the last stage of its trail, was confirmed that it had a powerful impact on curbing the effect of rheumatoid arthritis.

Roche cited a review which said, "The safety risk outweighs the benefits observed in these specific patient populations at this time after detecting serious and opportunistic infections, some of which were fatal".

National Rheumatoid Arthritis Society states that Rheumatoid arthritis is detected in 20 million people and results in stiff, swollen and painful joints after inflation caused by deficiency of immunity.


Latest News

U.S. Economic Growth Gets a Boost with New Home Building
Tesla May not Get an Opportunity to Open Stores in Michigan
Cuban role applauded by Kerry in Ebola fight
Travel restrictions can be caused by rising polio cases
Unprotected sex increases in final year of college
Amid Ebola fears in US, newspaper chooses to focus on India's 'health crisis'
Report Given by Nuclear Regulatory says Closure Plan of Yucca Mountain Meets Saf
Google’s Slowing Clicks on Ads Worry Investors and Analysts
Video games can actually help
Aussie’s chest burrowed by Bali spider
No reduction in atrial fibrillation with fish oil, new research finds
Existing protocols might not be enough for Ebola